Zarate CA Jr

Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, United States.

Zarate CA Jr

Effects of psychedelic drug use on neurocognitive function and the psychological and social domains of quality of life: an international online study.

Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies.

Treatments for Individuals with Suicidal Thoughts: Use, Indications, and Helpfulness.

Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.

Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers.

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.

Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.

Mu-Opioid Signaling Engagement as a Candidate Maintenance Mechanism for Prolonging Ketamine's Antisuicidal Effects.

Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine.

Bifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment.

Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial.

Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic.

Can ketamine and other glutamate receptor modulators be considered entactogens?

Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?

Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials.

Personalized use of ketamine and esketamine for treatment-resistant depression.

A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers.

Esketamine in depression: putative biomarkers from clinical research.

Exploring the impact of music on response to ketamine/esketamine: A scoping review.

Long-term follow-up of participants in ketamine clinical trials for mood disorders.

Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies.

Ketamine in neuropsychiatric disorders: an update.

Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.

Response to "Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis."

Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.

The role of dissociation in ketamine's antidepressant effects.

The influence of ketamine on drug discovery in depression.